Search Results (196)

Breast cancer is one of the leading causes of cancer deaths in women worldwide. Neoadjuvant chemotherapy (NACT) has increased rates of breast-conserving procedures and enabled the identification of patients with a particularly poor prognosis. Achieving a pathological complete response (pCR), an indicator of NACT efficacy, contrasts with residual disease (RD), which identifies patients at higher risk of recurrence. This review provides an overview of current evidence on the clinical and prognostic significance of pCR and RD in patients receiving NACT for breast cancer. The analysis is based on data from randomized clinical trials, meta-analyses, and current clinical guidelines for contemporary systemic treatment. Pathological complete response varies according to tumor subtype, with the highest rates observed in triple-negative and non-luminal HER2-positive breast cancer. In HER2-positive disease, the combination of chemotherapy with HER2-targeted therapies increases pCR rates, while the presence of RD supports escalation of postoperative treatment with antibody–drug conjugates. In triple-negative breast cancer (TNBC), the inclusion of platinum agents and immune checkpoint inhibitors improves treatment efficacy. In HER2-negative breast cancer and germline BRCA1/2 mutations, adjuvant PARP inhibitors improve survival independently of pCR, highlighting the complex relationship between pathological response and prognosis. Immunotherapy and targeted therapies are used alongside standard chemotherapy and hormone therapy in perioperative treatment. Further research is required to refine response assessment, integrate new biomarkers such as circulating tumor DNA (ctDNA), and optimize treatment selection, while clarifying the significance of reassessing hormone receptor and HER2 status in residual disease and its impact on subsequent treatment decisions. Full article

Background/Objectives: The clinical management of ductal carcinoma in situ (DCIS) remains controversial due to its heterogeneous biological behavior and uncertain risk of progression. Standard treatment often includes surgery and radiotherapy, although the actual recurrence risk varies considerably among patients. This study aimed to evaluate recurrence patterns and associated clinicopathological factors in a large single-center cohort of patients with pure DCIS. Methods: We retrospectively analyzed 403 patients with histologically confirmed pure DCIS treated with breast-conserving surgery or mastectomy between 2016 and 2023. Clinical, imaging, pathological, and treatment-related variables were assessed. Descriptive and exploratory comparative analyses were performed between patients with and without ipsilateral recurrence. Results: A total of 417 lesions were analyzed, with 21 ipsilateral recurrences (5%) observed during follow-up. Among recurrent cases, 57% were non-invasive recurrent DCIS and 38% were invasive carcinomas. Most recurrences occurred in patients treated with breast-conserving surgery, and 52% of recurrent patients had not received adjuvant radiotherapy. All recurrent cases were estrogen receptor–positive at initial diagnosis, whereas none had received endocrine therapy. No clear association between recurrence patterns and tumor grade or tumor size emerged in this exploratory analysis. No distant metastases or disease-related deaths were observed during follow-up. Conclusions: Recurrence after treatment for pure DCIS was relatively uncommon and frequently non-invasive. Traditional clinicopathological variables alone appeared insufficient to consistently identify recurrence patterns in this cohort. These findings support the need for more individualized risk stratification approaches integrating clinical, imaging, and molecular factors in order to reduce potential overtreatment in selected patients with DCIS. Full article

Breast cancer surgical management encompasses a spectrum of options that extend beyond oncologic control and carry substantially different cumulative surgical burdens. Although breast-conserving therapy (BCT) and mastectomy offer equivalent survival outcomes in many clinical scenarios, the downstream implications of these choices, including the number of operations, complication profiles, recovery timelines, and need for revision, are often underrecognized during initial treatment planning. This review aims to provide non-plastic surgeons with a practical framework for understanding the surgical burden associated with BCT compared with mastectomy and, when mastectomy is selected, the implications of subsequent reconstructive pathways. By discussing breast cancer surgery through the lens of cumulative surgical burden rather than isolated procedural choices, this review seeks to support more informed, multidisciplinary counseling and shared decision-making. A clearer understanding of reconstructive trajectories may help align surgical recommendations with patient values, optimize expectations, and reduce unanticipated downstream interventions across the continuum of breast cancer care. Full article

Background/Objectives: To evaluate the effectiveness of manual lymph drainage (MLD) in treating breast edema in patients who have undergone breast-conserving surgery and adjuvant radiotherapy. Methods: Twenty-five female participants who underwent breast-conserving surgery and received adjuvant radiotherapy were enrolled in the study. Twelve participants were assigned to the treatment group (education, compression, exercise therapy, and MLD), and 13 to the control group (education, compression, and exercise therapy). The participants were assessed after radiotherapy (baseline) and three months post-treatment. The following variables were evaluated: general body pain, fatigue, breast pain, breast edema (breast edema questionnaire and LENT-SOMA-breast criteria), anxiety, depression, and quality of life. Results: In both groups, within-group analyses showed improvements in general body pain, fatigue, breast pain, breast edema, anxiety, depression, and some quality of life subscales (p < 0.05). Between-group comparisons revealed additional improvements in breast pain, breast edema, and breast-related criteria in the treatment group compared with the control group (p < 0.05). Additionally, the treatment group showed greater improvements in some quality of life subscales (global health status, fatigue, pain, systemic treatment side effects, and breast and arm symptoms) compared with the control group (p < 0.05). Conclusions: The addition of MLD may provide additional benefits within complex decongestive therapy for breast edema following breast-conserving surgery and radiotherapy. However, these findings should be considered preliminary and interpreted with caution due to the small sample size, lack of objective outcome measures, absence of a no-treatment control group, and lack of blinding of participants and treating clinicians. As both groups received active treatment during a period of expected natural recovery, the independent effect of MLD cannot be fully isolated. Confirmation in future well-designed, blinded randomized controlled trials incorporating objective outcome measures is warranted. Full article

The optimal management of patients with limited sentinel lymph node metastasis in breast cancer, particularly regarding whether to perform additional axillary surgery, continues to be an area of clinical uncertainty in routine practice. This multicenter retrospective cohort study aimed to evaluate adherence to ACOSOG Z0011 criteria and the oncological safety of omitting ALND in a Chinese population. We included 462 women with clinical stage T1–2N0 breast cancer who underwent breast-conserving surgery and were found to have 1–2 positive SLNs between January 2013 and December 2021. All patients received adjuvant radiotherapy and systemic therapy. Patients underwent either sentinel lymph node biopsy alone (SLNB; n = 274, 59.3%) or SLNB followed by ALND (n = 188, 40.7%). Propensity score matching (1:1) was applied to balance baseline characteristics, yielding 152 matched pairs. Disease-free survival (DFS) was the primary endpoint. No significant difference in DFS was observed between the SLNB alone and SLNB + ALND groups in either the overall cohort or the matched cohort. Multivariable Cox regression analysis confirmed that the type of axillary surgery was not independently associated with DFS in patients with 1–2 positive SLNs treated with breast-conserving surgery. Logistic regression analysis indicated that surgeons were more likely to perform ALND in patients with a higher SLN tumor burden; compared with micrometastasis, macrometastasis in 1–2 SLNs and a sentinel lymph node metastasis ratio greater than one-third were significantly associated with the selection of ALND. These findings suggest that omission of ALND was not associated with a statistically significant difference in DFS and provide real-world evidence supporting the applicability of Z0011-based axillary management in the Chinese population; however, given the observational design and potential for residual confounding, these results should be interpreted with caution. Full article

Breast-conserving therapy, consisting of lumpectomy followed by adjuvant radiotherapy, is the standard of care for early-stage breast cancer, providing oncologic outcomes equivalent to mastectomy while preserving breast anatomy and quality of life. Radiotherapy remains a cornerstone of treatment across disease stages, significantly reducing local recurrence rates and improving long-term survival. Advances in radiotherapy techniques—including conventional fractionation, hypofractionation, tumor-bed boost delivery, and regional nodal irradiation—have optimized oncologic efficacy while inducing a broad spectrum of time-dependent morphological changes in breast tissue. Accurate imaging surveillance is therefore essential to distinguish expected post-radiotherapy changes from tumor recurrence and to avoid unnecessary diagnostic or therapeutic interventions. This review provides a comprehensive overview of contemporary breast radiotherapy protocols, their impact on post-treatment imaging appearances, and current recommendations for imaging surveillance. Characteristic findings across mammography, ultrasound, magnetic resonance imaging, and nuclear medicine modalities are discussed, with emphasis on their temporal evolution from acute inflammatory changes to chronic fibrosis, fat necrosis, and architectural distortion. Recognition of these imaging patterns, together with integration of radiotherapy-related parameters into image interpretation, is crucial for accurate diagnosis, early detection of recurrence, and informed clinical management of breast cancer survivors. Full article

Biological heterogeneity among different breast cancer (BC) subtypes results in markedly varying clinical outcomes. Identification and analysis of key gene biomarkers that are differentially regulated during radiation therapy (RT) may pose multiple clinical challenges for BC treatment. The purpose of the study is to identify and analyze the expression of key gene biomarkers and their networks that are differentially regulated after hypofractionated RT. Patients with BC (cT0-T2, N0, M0) were treated with hypofractionated whole breast RT 25 Gy in five fractions, 4 to 8 weeks before breast conservation surgery (BCS). Biopsy (pre-RT; n = 5) and surgical (post-RT; n = 14 or 15) BC tumor samples were used for NanoString targeted sequencing. We identified 165 and 244 differentially expressed genes (DEGs; p < 0.05) in BC tumor samples from BC patients post-RT using the nCounter BC360 and IO360 panels, respectively. Gene networks and pathway analysis revealed that RT increases the gene signature of tumor inflammation (TIS), cytotoxicity, and apoptosis, while downregulating the gene signatures of tumor cell proliferation, differentiation, and cell adhesion, and increases the claudin-low gene score. RT-induced mammary stemness and enhanced infiltration of stroma, mast, and macrophage cells in the BC tumor microenvironment (TME). Further, the nCounter IO360 (immuno-oncology) panel analysis validated the findings of BC360 and demonstrated that RT increased the myeloid inflammation signature and chemokine expression, modulated B, T, NK, and DC cell activities, and enhanced residual cancer burden (RCB) in BC tumors, thus creating an immunosuppressive TME. Collectively, RT sensitized BC tumors by increasing the gene signature of TIS, cytotoxicity, apoptosis, and mammary stemness. RT facilitated an immunosuppressive environment and increased RCB, suggesting that the therapeutic potential of RT is highly individualized for each patient based on their unique tumor biology, genetic makeup, and TME. Full article

Breast-conserving therapy (BCT), consisting of lumpectomy followed by adjuvant radiation, provides oncologic outcomes equivalent to mastectomy for many patients with breast cancer. As survivorship increases, the demand for aesthetic restoration after BCT has grown; however, reconstructive strategies in this setting remain less standardized than those following mastectomy. Reconstruction after BCT presents distinct challenges due to partial tissue loss, nonuniform radiation injury, progressive fibrosis, and wide variability in patient expectations and tolerance for revision surgery. Consequently, mastectomy-based reconstructive algorithms are often insufficient for guiding care in this population. This review synthesizes contemporary reconstructive options following BCT through a personalized medicine framework, emphasizing patient-specific risk factors that influence technique selection, timing, and long-term outcomes. Key determinants include radiation exposure, breast morphology, comorbid conditions, prior breast surgery, and psychosocial preferences. Oncoplastic volume displacement, implant-based augmentation, fat grafting, and autologous reconstruction each demonstrate distinct risk profiles in the post-BCT tissue environment and require individualized application. Timing of reconstruction and willingness to undergo staged procedures play a central role in outcome durability and patient satisfaction. Across reconstructive strategies, revision burden emerges as a clinically meaningful, patient-centered outcome that is not adequately captured by traditional short-term complication metrics. A risk-informed approach that integrates individualized risk assessment with transparent counseling and shared decision-making may improve alignment between reconstructive planning and patient goals. Personalized reconstruction after BCT requires moving beyond technique-driven paradigms toward flexible, longitudinal care pathways. Future efforts should focus on developing BCT-specific predictive models and incorporating patient-reported outcomes to advance personalized reconstructive care. Full article

Background: Patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) derive a greater benefit from endocrine therapy than patients with ER-negative disease. The relevance of ER status and progesterone receptor (PR) status in DCIS to radiation therapy has not been well explored. Methods: Patients undergoing breast-conserving surgery with or without radiation were grouped by ER and PR status and matched using rank-based Mahalanobis optimal matching with respect to lesion size and grade and patient age and race. Cumulative incidences were estimated and competing risk regressions with subdistribution hazard ratios (sHRs) were calculated. Results: Among patients who underwent breast-conserving surgery only, 369 patients with ER-PR- disease were matched to 738 patients with ER+PR+ disease (1:2 matching). In multivariate models, patients with ER-PR- disease were at increased risk of any invasive events (sHR = 2.47, p = 0.007) and early ipsilateral invasive events (sHR = 2.64, p = 0.02 in the 0-to-4-year period) relative to patients with ER+PR+ disease. Among patients who underwent breast-conserving surgery with adjuvant radiation, 1498 patients with ER+PR+ disease were matched to 1498 patients with ER-PR- disease. No significant differences were noted with respect to cumulative incidence of any invasive event (5.6% vs. 5.6%) or ipsilateral invasive events (1.9% vs. 2.9%). In multivariate models, no significant differences were noted. Patients with ER-PR+ lesions had similar cumulative incidences of ipsilateral invasive events to patients with ER-PR- disease in the absence of radiation (5.9% vs. 5.9%) and similar cumulative incidences of contralateral invasive events to patients with ER+PR+ disease when radiation was administered (3.2% vs. 4.2%). Conclusion: The statuses of ER and PR carry independent prognostic and therapeutic implications beyond those of traditional clinicopathologic risk factors. Given that ER and PR statuses are routinely collected for patients with DCIS, incorporation of these variables into clinicopathologic risk classification systems is warranted. Full article

Background and Objectives: The aim of this retrospective cohort study was to determine the frequency of early-stage nipple necrosis and wound complications in patients undergoing unilateral skin-sparing mastectomy (SSM) and direct implant-based reconstruction and describe the conservative/advanced wound care approaches used for these complications. Materials and Methods: A retrospective review was made of the medical records of 84 patients who underwent same-session unilateral SSM and implant-based reconstruction in the Surgical Oncology Clinic between November 2019 and February 2024. Statistical analyses were performed using the Shapiro–Wilk test, Mann–Whitney U-test, and Chi-square/Fisher tests. Results: The mean age of the patients was 43.51 ± 6.5 years, 35.7% of the patients received neoadjuvant chemotherapy, and smoking prevalence was 7.1%. Wound complications developed in 16.7% of the patients, distributed as follows: wound dehiscence 6%, NAC necrosis 8.4%, infection 1.2%, and hematoma 1.2%. Interventions due to complications were performed at rates of 2.4% for areola excision, 2.4% for debridement, and 2.4% for implant excision. The only variable significantly associated with complication development was excision volume, which was higher in the complication group (p = 0.033). Logistic regression analysis showed that a one-unit increase in excision volume was associated with a statistically significant increase in the likelihood of complication development (O.R = 1.002; 95% CI: 1.000–1.004; p = 0.019). No significant association was found between age, height/weight, neoadjuvant therapy, smoking, breast side, pathology subtype, axillary approach, and the development of complications (p > 0.05). Advanced wound management was provided in 10 of the 14 cases (71.4%) that developed complications. Conclusions: Excision volume was found to be the only variable associated with wound complication development after implant-based reconstruction following unilateral SSM. Most complications were managed successfully with advanced wound care, minimizing the need for re-operation. For patients undergoing high-volume excision, risk-based early multidisciplinary, close follow-up is recommended. Full article

This 12-year retrospective study compared oncoplastic breast-conserving surgery (OBCS) with lumpectomy without reconstruction (LNR) to evaluate surgical and oncological outcomes. OBCS combines tumour removal with tissue reshaping to preserve breast contour, but concerns about treatment delays and recurrence limit its use. Among 1880 patients reviewed between 2008 and 2020, 1290 met the inclusion criteria—307 (24%) underwent OBCS and 983 (76%) underwent LNR. Women receiving OBCS were younger (mean 56 vs. 61 years, p < 0.0001) with similar BMIs. OBCS was associated with a slightly longer time to radiotherapy (3.93 vs. 3.57 months, p = 0.01) and higher rates of minor complications such as wound infection (7.17% vs. 3.66%), dehiscence (4.89% vs. 0.92%), and fat necrosis (11.73% vs. 1.12%) (all p < 0.0001). There were no significant differences in positive margins, mastectomy conversion, recurrence, or disease-free survival. Despite a modest delay in adjuvant therapy and increased minor complications, OBCS demonstrated equivalent oncologic safety to standard lumpectomy. These findings support OBCS as a safe breast-conserving option that maintains esthetic outcomes without compromising cancer control, encouraging its broader use in appropriately selected patients. Full article

Studies that have sought to describe and account for pre-diagnosed depressive symptoms on BC treatment choice, delay in initiating treatment, and mortality have been inconsistent. The purpose of the study is to examine the association between pre-diagnosed depressive symptoms and their impact on breast cancer (BC) treatment, treatment delays, and mortality. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey (SEER-MHOS) dataset among women aged 65 years and older diagnosed with BC. Among 3840 eligible patients, 28.1% had pre-diagnosed depressive symptoms. Patients with pre-diagnosed depressive symptoms who were diagnosed with early-stage BC were significantly more likely (OR = 1.52; 95% CI: 1.26–1.84) to undergo mastectomy or receive breast-conserving surgery (BCS) alone rather than BCS plus radiation therapy (RT) compared to patients who were not pre-diagnosed with depressive symptoms. Among patients with advanced-stage BC, pre-diagnosed depressive symptoms were not significantly associated with treatment type. Among Hispanic patients, pre-diagnosed depressive symptoms were associated with treatment delays. Overall, patients with pre-diagnosed depressive symptoms had a 16% increased adjusted risk of BC-related mortality compared to those who were not pre-diagnosed with depressive symptoms, and those with advanced-stage cancer had an 18% higher adjusted risk of death than early-stage BC. Conclusions: Overlooking depressive symptoms management prior to a breast cancer diagnosis may result in poorer survival outcomes. Early detection and consistent management of depression are critical for improving patient survival. Full article

Background: Long-term real-world data on breast cancer outcomes in North Africa remain limited, despite rising incidence and increasing access to multimodal treatment. This study reports survival outcomes, recurrence patterns, and quality-of-care performance in the largest single-center breast cancer cohort in the region. Methods: A retrospective analysis was conducted on a prospectively maintained registry of 1826 women who underwent curative-intent breast cancer surgery between 2002 and 2016. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan–Meier methods. Prognostic factors were examined through univariate and multivariate Cox regression analysis. Adherence to selected EUSOMA quality indicators was assessed across two time periods. Results: At a median follow-up of 10 years, five-year OS and DFS were 96% and 90%, respectively, declining to 91% and 84% at 10 years. Local recurrence occurred in 6.2% of patients and distant metastasis in 11%, with bone being the most frequent metastatic site. TNM stage, tumor size, SBR grade, and tumor localization were independent predictors of OS, while younger age and TNM stage independently predicted DFS. Hormone receptor status and TNM stage were associated with local recurrence; age and tumor site predicted distant metastasis. Quality-of-care evaluation showed high adherence to EUSOMA indicators, including timeliness of surgery, proportion of single-operation resections, and use of postoperative radiotherapy after breast-conserving surgery. Limited administration of HER2-targeted therapy during the earlier years of the cohort reflected historical availability constraints rather than current practice. Conclusions: This study provides robust long-term evidence from North Africa, demonstrating that high survival rates can be achieved when standardized surgical pathways, multidisciplinary coordination, and adherence to quality indicators are maintained. The findings underline the importance of sustained investment in diagnostic access and treatment organization and highlight the expected benefits of the expanded availability of HER2-targeted therapies in the region. These results offer a valuable benchmark for strengthening breast cancer care in comparable LMIC settings. Full article

Objectives: The aim of the study was to assess the impact of oncological treatment including surgery and radiotherapy on the respiratory function and quality of life of women treated for breast cancer, considering the effects of physiotherapy and additional inspiratory muscle training. Methods: A quantitative, repeated-measures study included 26 women (aged 30–69) with breast cancer who had undergone breast-conserving surgery and radiotherapy, randomly assigned to an IMT group or a sham IMT group. The following tests were performed on each patient: respiratory function, respiratory muscle strength, the WHOQOL-Bref questionnaire. The tests were performed five times as follows: before surgery, after surgery (4–6 days), before the start of radiotherapy (4–5 weeks after surgery), after the end of radiotherapy, and follow-up 4 weeks after the end of radiotherapy. Group I-IMT: patients underwent physiotherapy according to hospital rehabilitation standards and inspiratory muscle strength training at 15–60% PI_max. Group II-sham-IMT: patients underwent physiotherapy according to hospital rehabilitation standards and inspiratory muscle strength training at 15% PI_max. Results: After the surgery, a reduction in all parameters was observed, which improved gradually and depending on the group after physiotherapy and inspiratory muscle training. The PI_max value decreased significantly after the procedure in both groups (p = 0.00), but its significant increase after 4 weeks and radiotherapy (p = 0.00) was noted only in the I-IMT group. The quality of life assessed by women (WHO1) was significantly higher (p = 0.009) only in the group using IMT training with a load of 60% PI_max. Conclusions: Radical breast cancer treatment, including surgery and radiotherapy, significantly impairs respiratory function and quality of life in women, with the greatest deterioration observed after surgery. The use of prehabilitation and postoperative physiotherapy reduces the adverse effects of radical treatment, while additional inspiratory muscle training supports the improvement of respiratory function and the subjective assessment of quality of life in patients. Full article

Background and purpose: The role of adjuvant radiation therapy (RT) in early-stage HER2-positive breast cancer treated with breast-conserving surgery (BCS) and systemic therapy remains uncertain in the era of HER2-targeted regimens. This study evaluates the survival impact of RT in patients aligned with the HERO RT de-escalation trial (NRG-BR008). Materials and methods: We queried the National Cancer Database for patients with early-stage HER2-positive invasive breast carcinoma treated with BCS and systemic therapy, stratified into HERO trial-aligned cohorts: Arm 1 (adjuvant systemic therapy) vs. Arm 2 (neoadjuvant systemic therapy, pathologic complete response). Within each cohort, patients receiving adjuvant RT were compared with those omitting RT. In the primary analysis, patients were propensity score matched (PSM) on demographics, diagnosis years, tumor characteristics, and trial stratification variables. Inverse probability of treatment weighting (IPTW) was additionally performed as a sensitivity analysis. Overall survival was evaluated using Kaplan–Meier, Cox regression, and restricted mean survival time (RMST). Results: In Arm 1 (818 patients, 94 deaths), 5-year OS was 96.9% with RT vs. 88.0% without RT, and 10-year OS was 94.3% vs. 68.5% (log-rank p < 0.001). RT omission was associated with higher mortality in the PSM Cox model (HR, 4.78; 95% CI, 2.84–8.02; p < 0.001), with an RMST advantage favoring RT of +2.86 months at 5 years and +12.55 months at 10 years (p < 0.001). In Arm 2 (176 patients, 10 deaths), 5-year OS was 97.6% with RT vs. 91.1% without RT, and OS at 107 months was 94.8% vs. 91.1% (log-rank p = 0.13). RT omission was not statistically significant in the PSM Cox model (HR, 3.40; 95% CI, 0.82–14.05; p = 0.09), though RMST favored RT (+1.83 months at 5 years, p = 0.004; +3.91 months at 107 months, p = 0.03). IPTW analyses were directionally consistent in Arm 1 (HR, 3.26; 95% CI, 2.52–4.21; p < 0.001) and inconclusive in Arm 2 (HR, 1.78; 95% CI, 0.80–3.95; p = 0.16). Conclusions: In this HERO-aligned national cohort, RT omission was associated with inferior OS in patients treated with adjuvant systemic therapy after BCS. Findings in the neoadjuvant pCR cohort were imprecise and hypothesis-generating. Given the retrospective registry design, lack of recurrence-specific endpoints, and potential residual confounding, results should not be interpreted as causal but support continued RT use outside prospective de-escalation trials. Full article